Recruiting

Measles Vaccine

Sponsor:

Children's Hospital Medical Center, Cincinnati

Code:

NCT07356050

Conditions

Sickle Cell Disease

Measles Vaccination

Sickle Cell Anemia

Eligibility Criteria

Sex: All

Age: 0 - 6

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Conditions

Sickle Cell Disease

Measles Vaccination

Sickle Cell Anemia

Study ID

NCT07356050

Start date

Mar 13, 2025

Status verified date

Jan, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 6

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.

Exclusion Criteria:

1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.

Study Design

Enrollment

130 participants

Anticipated

Interventions and Outcome Measures

Arms

Second Measles Vaccine (MV2)

Participants who receive second measles vaccine.

First Measles Vaccine (MV1)

Participants who obtain the first measles vaccine.

Primary outcome measure

  • Measles Seroconversion Rates 8 Weeks After MV1 and MV2 Vaccinations [ Time Frame: From enrollment to the end of sample collection at 8 weeks ]

Central Contacts and Locations

Central contacts

Teresa Latham

513-803-7922Teresa.Latham@cchmc.org

Amy Shova

(513) 803-1917Amy.Shova@cchmc.org

Locations

Cincinnati Children's Hospital Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

Contacts

MacKenzie Tasset

513-803-4856MacKenzie.Tasset@cchmc.org

Principal Investigator:

Charles Quinn, MD

More Information

Sponsor

Children's Hospital Medical Center, Cincinnati

Last update posted

Jan 21, 2026

Last verified

Jan, 2026

Keywords

  • Measles Vaccine Immunogenicity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Children's Hospital Medical Center, Cincinnati on 2026-01-21.